C
Caroline M. van Rij
Researcher at Erasmus University Rotterdam
Publications - 14
Citations - 2721
Caroline M. van Rij is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Medicine & Chemoradiotherapy. The author has an hindex of 8, co-authored 10 publications receiving 1905 citations. Previous affiliations of Caroline M. van Rij include Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
Joel Shapiro,J. Jan B. van Lanschot,Maarten C.C.M. Hulshof,Pieter van Hagen,Mark I. van Berge Henegouwen,Bas P. L. Wijnhoven,Hanneke W. M. van Laarhoven,Grard A. P. Nieuwenhuijzen,Geke A. P. Hospers,Johannes J. Bonenkamp,Miguel A. Cuesta,Reinoud J. B. Blaisse,Olivier R. Busch,Fiebo J. W. ten Kate,Geert-Jan Creemers,Cornelis J. A. Punt,John T. M. Plukker,Henk M.W. Verheul,Ernst Jan Spillenaar Bilgen,Herman van Dekken,Maurice J.C. van der Sangen,Tom Rozema,Katharina Biermann,Jannet C. Beukema,Anna H.M. Piet,Caroline M. van Rij,Janny G. Reinders,Hugo W. Tilanus,Ewout W. Steyerberg,Ate van der Gaast +29 more
TL;DR: Long-term follow-up confirms the overall survival benefits for neoadjuvant chemoradiotherapy in patients with clinically resectable, locally advanced cancer of the oesophagus or Oesophagogastric junction and shows a significant increase in 5-year overall survival.
Journal ArticleDOI
Patterns of Recurrence After Surgery Alone Versus Preoperative Chemoradiotherapy and Surgery in the CROSS Trials
Vera Oppedijk,Ate van der Gaast,J. Jan B. van Lanschot,Pieter van Hagen,Rob M. van Os,Caroline M. van Rij,Maurice J.C. van der Sangen,Jannet C. Beukema,H.J.T. Rutten,Patty H. Spruit,Janny G. Reinders,Dick J. Richel,Mark I. van Berge Henegouwen,Maarten C.C.M. Hulshof +13 more
TL;DR: Preoperative CRT in patients with esophageal cancer reduced locoregional recurrence and peritoneal carcinomatosis and there was a small but significant effect on hematogenous dissemination in favor of the CRT group.
Journal ArticleDOI
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
Ben M Eyck,J. Jan B. van Lanschot,J. Jan B. van Lanschot,Maarten C.C.M. Hulshof,Berend J van der Wilk,Joel Shapiro,Pieter van Hagen,Mark I. van Berge Henegouwen,Bas P. L. Wijnhoven,Hanneke W. M. van Laarhoven,Grard A. P. Nieuwenhuijzen,Geke A. P. Hospers,Johannes J. Bonenkamp,Miguel A. Cuesta,Reinoud J. B. Blaisse,Olivier R. Busch,Geert-Jan Creemers,Cornelis J. A. Punt,Cornelis J. A. Punt,John T. M. Plukker,Henk M.W. Verheul,Henk M.W. Verheul,Ernst Jan Spillenaar Bilgen,Maurice J.C. van der Sangen,Tom Rozema,Fiebo J. W. ten Kate,Jannet C. Beukema,Anna H.M. Piet,Caroline M. van Rij,Janny G. Reinders,Hugo W. Tilanus,Ewout W. Steyerberg,Ewout W. Steyerberg,Ate van der Gaast +33 more
TL;DR: Chemoradiotherapy for esophageal cancer followed by surgery study (CROSS) has become a standard of care for patients with locally advanced resusceptible cancer in this paper.
Journal ArticleDOI
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
Bo Jan Noordman,Manon C.W. Spaander,Roelf Valkema,Bas P. L. Wijnhoven,Mark I. van Berge Henegouwen,Joel Shapiro,Katharina Biermann,Ate van der Gaast,Richard van Hillegersberg,Maarten C.C.M. Hulshof,Kausilia K. Krishnadath,Sjoerd M. Lagarde,Grard A. P. Nieuwenhuijzen,Liekele E. Oostenbrug,Peter D. Siersema,Peter D. Siersema,Erik J. Schoon,Meindert N. Sosef,Ewout W. Steyerberg,Ewout W. Steyerberg,J. Jan B. van Lanschot,Michael Doukas,Nanda C. Krak,Jan-Werner Poley,Caroline M. van Rij,Jaques Jghm Bergman,Suzanne S. Gisbertz,Hanneke W. M. van Laarhoven,Sybren L. Meijer,Lucas Goense,Nadia Haj Mohammad,Monique G.G. Hobbelink,G. Johan A. Offerhaus,Frank P. Vleggaar,Wouter L. Curvers,Geert-Jan Creemers,Mark J. Roef,Maurice J.C. van der Sangen,Jeroen Buijsen,Robert G. Riedl,Wendy M. J. Schreurs,Fabiënne A. R. M. Warmerdam,Mjr Janssen,Chella Van Der Post,Sandra A Radema,Camiel Rosman,H.J.T. Rutten +46 more
TL;DR: The correlation between clinical response during clinical response evaluations and the final pathological response in resection specimens was shown, as shown by the proportion of tumour regression grade (TRG) 3 or 4 residual tumours that was missed duringclinical response evaluations.
Journal ArticleDOI
Impact of a multidisciplinary tumour board meeting for upper-GI malignancies on clinical decision making: a prospective cohort study
Pieter van Hagen,Manon C.W. Spaander,Ate van der Gaast,Caroline M. van Rij,Hugo W. Tilanus,J. Jan B. van Lanschot,Bas P. L. Wijnhoven +6 more
TL;DR: In over 1/3 of cases, the diagnostic work-up or treatment plan is altered after evaluation by a multidisciplinary tumour board.